GATA3 is a sensitive marker for primary genital extramammary paget disease: An immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15 by Cao, Dengfeng & et al,




GATA3 is a sensitive marker for primary genital
extramammary paget disease: An
immunohistochemical study of 72 cases with
comparison to gross cystic disease fluid protein 15
Dengfeng Cao
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Cao, Dengfeng and et al, ,"GATA3 is a sensitive marker for primary genital extramammary paget disease: An immunohistochemical
study of 72 cases with comparison to gross cystic disease fluid protein 15." Diagnostic Pathology.12,1. 51. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6032
RESEARCH Open Access
GATA3 is a sensitive marker for primary
genital extramammary paget disease: an
immunohistochemical study of 72 cases
with comparison to gross cystic disease
fluid protein 15
Ming Zhao1†, Lixin Zhou2†, Li Sun2, Yan Song3, Yunquan Guo4, Xun Zhang3, Feng Zhao4, Peng Wang5,
Junqiu Yue6, Dongfeng Niu2, Zhongwu Li2, Xiaozheng Huang2, Qiang Kang2, Lin Jia2, Jinping Lai7
and Dengfeng Cao8*
Abstract
Background: GATA-binding protein 3 (GATA3) has been identified as a sensitive marker for breast carcinoma but
its sensitivity in primary genital extramammary Paget diseases (EMPDs) has not been well studied.
Methods: Here we investigated immunohistochemical expression of GATA3 in 72 primary genital EMPDs (35 from
female, 37 from male; 45 with intraepithelial disease only, 26 with both intraepithelial disease and invasive
adenocarcinoma including 14 also metastasis, 1 with metastatic adenocarcinoma only for study). We also compared
GATA3 to gross cystic disease fluid protein 15 (GCDFP15) for their sensitivity.
Results: Positive GATA3 staining was seen in all 71 (100%) intraepithelial diseases, 25/26 (96%; female 10/10,
male 15/16) invasive adenocarcinomas and 14/15 (93%; female 3/3, male 11/12) metastatic adenocarcinomas,
respectively. Positive GCDFP15 staining was seen in 46/71 (65%; female 28/34 or 82%, male 18/37 or 49%) intraepithelial
diseases, 20/26 (77%; female 9/10, male 11/16) invasive adenocarcinomas, and 12/15 (80%; female 2/3, male 10/12)
metastatic adenocarcinomas, respectively (GATA3 versus GCDFP15: p < 0.01 for both intraepithelial disease and invasive
adenocarcinoma, p = 0.28 for metastatic adenocarcinoma). In positive-stained cases, GATA3 stained more tumor cells
than GCDFP15 (79% versus 25% for intraepithelial disease, 71% vs 34% for invasive adenocarcinoma, 73% vs 50% for
metastatic adenocarcinoma, p < 0.01 for all 3 components).
Conclusions: Our findings indicate that GATA3 is a very sensitive marker for primary genital EMPDs and is more
sensitive than GCDFP15.
Keywords: GATA3, GCDFP15, Extramammary Paget disease, Immunohistochemical marker
* Correspondence: dcao@path.wustl.edu
†Equal contributors
8Department of Pathology and Immunology, Washington University School
of Medicine, 660 S South Euclid Avenue Campus Box 8118, Saint Louis, MO
63110, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhao et al. Diagnostic Pathology  (2017) 12:51 
DOI 10.1186/s13000-017-0638-z
Background
Paget disease (PD) is a distinct intraepidermal adenocar-
cinoma with a pagetoid growth pattern. PDs are classified
as mammary and extramammary subtypes according to
their locations and their relationship to breast [1, 2].
Mammary PDs account for 90% of the PDs occurring on
the skin of nipple/areola complex and most of them repre-
sent tumor spread to the epidermis from an underlying in-
vasive ductal carcinoma (53–60%) or ductal carcinoma in
situ (24–43%). Compared to breast PD, primary extra-
mammary PDs (EMPDs) are relatively uncommon and
their histogenesis is less clear [1, 2].
Primary EMPDS are found in areas rich in apocrine
glands. The most common site of primary EMPDs is
vulva followed by perianal skin, scrotum and penis, and
axilla etc. [1–6]. In women, more than 80% of primary
EMPDs are in the vulva [1–4, 6]. In men, approximately
half of EMPDs are in the penoscrotal region [4–8]. Most
primary EMPDs are intraepithelial at their initial presen-
tation (type Ia disease) but some have both intraepithe-
lial disease and invasive adenocarcinoma i.e. invasive
EMPDs [1–11]. The invasive adenocarcinomas seen in
primary EMPDs include those arising from intraepithe-
lial EMPD (type Ib disease) and those giving rise to the
intraepithelial disease (type Ic disease, underlying adeno-
carcinoma with subsequent epidermal involvement i.e.
Paget disease as manifestation of an underlying adeno-
carcinoma) [3]. Among patients with invasive EMPDs
(type Ib and type Ic), 20% to 40% had lymph node me-
tastasis [4–7, 9, 11]. Up to 17% to 50% patients with in-
vasive EMPDs also develop concurrent or subsequent
distant metastasis [4, 5, 7, 9–12].
Primary EMPDs should be distinguished from second-
ary EMPDs given their different treatment and prognosis
[3]. Secondary EMPD is usually the result of intraepithe-
lial spread from a visceral carcinoma located elsewhere,
with the gastrointestinal tract (colorectum) or urogenital
tract (urinary bladder, prostate) being the most 2 com-
mon sources [1–3, 9, 13–17]. EMPDs may also pose
some diagnostic challenges in metastatic sites as they
morphologically may mimic other tumors such as urothe-
lial carcinoma and breast carcinoma. This diagnostic chal-
lenge is further complicated by the fact that patients with
EMPDs have an increased risk of developing secondary
primary tumors in which breast carcinoma, colorectal
adenocarcinoma and urothelial carcinoma are among the
most common ones [4–6, 9, 14–17].
Given the overlapping morphologic features between
primary EMPDs and secondary ones, and between meta-
static EMPDs and their mimics in metastatic sites, immu-
nohistochemical markers are often needed to facilitate the
correct diagnosis. Several immunohistochemical markers,
including cytokeratin 7, carcinoembryonic antigen, andro-
gen receptor and c-erbB2 (HER2), have been used for
diagnosing primary EMPDs, however, their specificity is
relatively low [18–20] and therefore limited their diagnos-
tic utility in metastatic setting. Gross cystic duct fluid
protein 15 (GCDFP15, also known as BRST-2) shows
relatively high specificity for EMPDs but its sensitivity
was only 60% to 85% and in many cases the staining
was focal [21–26]. Primary EMPD is analogous to breast
Paget disease. Recently a transcription factor GATA-
binding protein 3 (GATA3) has been identified as a very
sensitive marker for breast carcinoma, both in both
primary and metastatic sites [27–31]. GATA3 was also
reported to be highly expressed in apocrine glands and
adnexal tumors [30]. Apocrine gland has been proposed
as the origin of primary EPMDs according to one theory
[1, 2, 21]. These findings suggest that GATA3 might be a
sensitive marker for primary EMPDs. In the literature,
there was only one recent report of GATA3 in 11 vulvar
primary EMPDs [32].
In this study, using immunohistochemical staining we
investigated the expression of GATA3 in a large series of
72 primary EMPDs (45 with intraepithelial disease only,
26 with both intraepithelial disease and invasive adenocar-
cinoma including 14 also with lymph node metastasis,
1 with metastatic adenocarcinoma only for study) in male
and female genital regions to explore the potential diag-
nostic utility of GATA3 in these tumors. We also com-




The surgical pathology archives of the authors’ hospitals
were searched for primary EMPDs in male and female
genital regions. A total of 72 surgically resected cases with
confirmed diagnosis of primary EMPDs in the genital re-
gion were included for this study: 35 from female and 37
from male patients. All 35 female cases were from vulva,
including 24 with intraepithelial disease only (type Ia dis-
ease), 10 with both intraepithelial disease and invasive
adenocarcinoma (5 type Ib, 5 type Ic, 2/5 type Ic cases
with metastatic adenocarcinoma in nodes) and 1 with only
metastatic node disease for study (history of primary vul-
var EMPD). No breast tissue or mammary-like gland was
present in the adjacent vulva tissue in any of these female
cases. The 37 male cases included 3 from penis, 1 from
perineum, and 33 from the scrotum. Twenty-one (21 or
57%) male cases were intraepithelial diseases, 16 (43%)
cases had both intraepithelial disease and invasive adeno-
carcinoma (14 type Ib, 2 type Ic; 12/16 also with nodal
metastasis including 11/14 type Ib and 1/2 type Ic).
Immunohistochemical staining
One to two formalin-fixed, paraffin-embedded full tissue
blocks from each case were retrieved to generate 4 um
Zhao et al. Diagnostic Pathology  (2017) 12:51 Page 2 of 10
unstained slides for immunohistochemical staining on a
Ventana Benchmark-XT automated stainer using the
Ventana ultraView DAB detection kit. The antibody to
GATA3 is a mouse monoclonal antibody (clone L50–
823, prediluted, Biocare, Concord, CA 94520). The anti-
body to GCDFP15 was a rabbit monoclonal antibody
(clone EP95, prediluted, Rocklin, CA 95677). The auto-
matic immunohistochemical reaction was performed
with Ventana Cell Conditioning Solution 1 (CC1) at
pH 6.0. The primary antibody (antibody to GATA3, anti-
body to GCDFP15) was incubated at 37 degrees for
24 min. Positive control (breast ductal carcinoma as
positive control) and negative control (incubation with
secondary antibody only) were included for each run of
immunostains. Only nuclear staining was considered
positive for GATA3. The staining pattern for GCDFP15
is cytoplasmic. The percentage of tumor cells labeled
was semi-quantitatively scored as 0 (<1% tumor cell
staining), 1+ (1–25%), 2+ (26–50%), 3+ (51–75%), and 4
+ (76–100%).
Statistical analysis
The Fisher exact test was used to compare the staining
pattern for GATA3 with GCDFP15, and paired t-test
was used to compare the mean percentage of tumor cells
stained with GATA3 with GCDFP15 in the intraepithe-
lial component, invasive component and metastatic
components of EMPDs. A P-value of <0.05 was consid-
ered statistically significant.
Results
Expression of GATA3 and GCDFP15 in female primary
extramammary Paget diseases
Among the 35 vulvar EMPDs, 24 had intraepithelial dis-
ease only, 10 had both intraepithelial disease and invasive
adenocarcinoma (2 also had regional lymph node metasta-
sis) and 1 had only the metastatic adenocarcinoma in one
lymph node for study (history of vulvar primary EMPD).
Among the 10 cases with both intraepithelial disease and
invasive adenocarcinoma, 5 were type Ib and 5 were type
Ic diseases (4 apocrine carcinomas and 1 eccrine carcin-
oma). The staining results of GATA3 and GCDFP15 for
each component of vulvar extra-mammary diseases are
summarized in Table 1.
All 34 intraepithelial disease components showed posi-
tive GATA3 staining (34/34, 100%), including 1+ in 2
(6%), 2+ in 1 (3%), 3+ in 3 (9%) and 4+ in 28 (82%), with
almost all cases demonstrating moderate to strong nu-
clear staining (Fig. 1). The invasive adenocarcinoma
showed positive GATA3 staining in all 10 cases (2+ in 2,
4+ in 8) (Figs. 2, 3). All 3 metastatic adenocarcinomas
from vulvar EMPDs showed 4+ GATA3 staining (Fig. 2).
Positive GCDFP15 staining was seen in 28 of 34 (82%)
intraepithelial disease components (1+ in 12/28, 2+ in 4/
28, 3+ in 4/28, 4+ in 8/28) and 9 of 10 (90%) invasive
adenocarcinomas (1+ in 3/10, 3+ in 1/10, and 4+ in 5/10;
5/5 type Ib disease, 4/5 type Ic disease) (Table 1, Figs. 2,
3). The only invasive adenocarcinoma that was negative
for GCDFP 15 staining was the eccrine carcinoma (type Ic
disease). Two of the 3 (66%) metastatic adenocarcinomas
showed positive GCDFP15 staining (1+, 4+) (Fig. 2).
Expression of GATA3 and GCDFP15 in male primary
extramammary Paget diseases
Among the 37 cases of male extra-mammary Paget dis-
eases, 33 were from the scrotum, 3 from the penis and 1
from the perineum. Twenty-one (57%) had intraepithe-
lial disease only. The remaining 16 cases (16/37 or 43%)
had both intraepithelial disease and invasive adenocar-
cinoma (14 type Ib, 2 type Ic) including 12 (12/16, 80%)
Table 1 Immunohistochemical staining results of GATA3 and GCDFP15 in primary vulvar extramammary Paget diseases
Disease Component GATA3 staininga GCDFP15 staininga P value
0 1+ 2+ 3+ 4+ Total 0 1+ 2+ 3+ 4+ Total
Intraepithelial disease
(N = 34)
0 2 (6%) 1 (3%) 3 (9%) 28 (82%) 34 (100%) 6 (8%) 12 (35%) 4 (12%) 4 (12%) 8 (24%) 28 (82%) 0.0004#
Type Ia (N = 24) 1 3 20 4 8 4 3 5
Type Ib (N = 5) 1 4 1 3 1
Type Ic (N = 5) 1 4 1 1 1 2
Invasive adenocarcinoma
(N = 10)
0 0 2 (20%) 0 8 (80%) 10 (10%) 1 (10%) 3 (30%) 0 1 (10%) 5 (50%) 9 (90%) 0.1035#
type Ib (N = 5) 5 1 1 3
type Ic (N = 5) 2 3 1 2 2
Metastatic adenocarcinoma
(N = 3)
0 0 0 0 3 (100%) 3 (100%) 1 (33%) 1 (33%) 0 0 1 (33%) 2 (67%) not
applicable
aThe staining is semi-quantitatively as follows: 0: <1% tumor cell staining; 1+: 1–25% tumor cells staining; 2+: 26–50% tumor cells staining; 3+: 51–75% tumor cells
staining; 4+: 76–100% tumor cells staining. NA non-applicable due to small number
#p value refers to comparison of staining patterns (0,1+,2+,3+,4+) not percentage of total positives
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with lymph node metastases. The staining results of
GATA3 and GCDFP15 for each component of male
extra-mammary diseases are summarized in Table 2.
Positive GATA3 staining was seen in all 37 intra-
epithelial disease components (100%), including 1+ in 4
(11%), 2+ in 2 (6%), 3+ in 2 (6%), and 4+ in 29 (78%)
(Fig. 1). The invasive adenocarcinomas showed positive
GATA3 staining in 15/16 (94%) cases including 1+ in 2
(12%), 2+ in 2 (12%), 3+ in 1 (6%) and 4+ in 10 (63%)
(Fig. 2). The invasive adenocarcinoma in type Ib disease
was positive for GATA3 in 13/14 cases (93%). The
underlying invasive adenocarcinomas in 2 type Ic
EMPDs were both positive for GATA3 (2+, 4+). Positive
GATA3 staining was seen in 11/12 (92%) metastatic
adenocarcinomas, including 1+ in 1 (8%), 2+ in 1 (8%), 3
+ in 1 (8%) and 4+ in 8 cases (67%) (Fig. 2).
Positive GCDFP15 staining was seen in 18 of 37 (51%)
intraepithelial disease components including 1+ in 12
(32%), 2+ in 4 (11%), and 4+ in 2 (6%) (Fig. 1). The inva-
sive adenocarcinomas showed positive GCDFP15 stain-
ing in 11 of 16 (69%) cases including 1+ in 6 (38%), 2+
in 1 (6%) and 4+ in 4 (25%). The invasive adenocarcin-
oma in Type Ib disease was positive for GCDFP15 in 9/
14 (64%, 1+ in 5/9, 4+ in 4/9) cases. The 2 invasive
adenocarcinomas in type IC EMPDs showed positive
GCDFP15 staining in both (1+, 2+). Positive GCDFP15
was seen in 10 of 12 (83%) metastatic adenocarcinomas
(1+ in 3/12, 2+ in 2/12, 3+ in 1/12, 4+ in 4/12) (Fig. 2).
Comparison of GATA3 to GCDFP15 in primary genital
extramammary Paget diseases
Among the 71 intraepithelial diseases (34 from female,
37 from male), all (100%) showed GATA3 staining
whereas only 46 of them (46/71 or 65%, female 28/34 or
82%, male 18/37 or 51%) showed positive GCDFP15
staining (p < 0.0001). Among the invasive adenocarcin-
omas, positive GATA3 and GCDFP15 staining was seen
in 25/26 (96%) and 18/26 (69%) cases, respectively
(p = 0.01). Among the 15 metastatic adenocarcinomas,
14 (93%) showed positive GATA3 staining and 12 (80%)
showed positive GCDFP15 staining (p = 0.2825).
Among the cases with positive immunohistochemical
staining, the mean percentage of positively stained
tumor cells in the intraepithelial diseases was 79% (fe-
male 83%, male 76%) for GATA3 and it was 25% (female
35%, male 10%) for GCDFP15 (p < 0.001). As far as the
invasive adenocarcinomas were concerned, the mean
percentage of tumor cells positive for GATA3 and
GCDFP15 was 71% (female 76%, male 68%) and 34% (fe-
male 42%, male 34%), respectively (p < 0.001). The mean
percentage of GATA3-positive metastatic adenocarcin-
oma cells was 73% (female 90%, male 68%) and it was
50% for GCDFP15 (female 65%, male 48%) (p < 0.01).
Expression of GATA3 in normal epidermal cells
Positive GATA3 staining was seen in some normal epi-
dermal cells in 22/34 (65%) female and 22/37 (60%)
cases, respectively, mainly in the spinous layer (typically
focal but occasionally diffuse) with occasionally in the
basal layer. Among the GATA3 positive cases, the
GATA3 staining intensity in the normal epidermal cells
was weaker than that in PD in 16/22 (73%) female and
17/22 (77%) cases, respectively. Similar GATA3 staining
intensity was seen in the normal epidermal cells and in
the intraepithelial PD cells in 6 of 22 (27%) female and 5
of 22 (23%) male cases, respectively. The intraepithelial
PD cells typically have larger nuclei than normal epider-
mal cells. However, in 2 cases in each gender, the
Fig. 1 Immunohistochemical staining of GATA3 and GCDFP15 in primary extramammary Paget diseases in the genital region: all intraepithelial
diseases in both genders (A1, vulva; B1, scrotum) were positive for GATA3 (A2, B2). Most of intraepithelial diseases (50% male, 82% female) were
also positive for GCDFP15 (A3, B3). GCDFP15 staining is often focal (B3)
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intraepithelial PD cells focally have small nuclei and in
these areas it is difficult to distinguish the intraepithelial
PD cells from normal epidermal cells just based on im-
munohistochemical staining. Their distinction relies on
the growth pattern.
Discussion
In this study, we investigated the immunohistochemical
expression of GATA3 in a large series of 72 primary
EMPDs in male and female genital regions. We found
that GATA3 was highly expressed in the primary genital
EMPDs. The high sensitivity of GATA3 is not only
present in the intraepithelial disease (100%) but also in
the invasive adenocarcinomas (96%) and metastatic
adenocarcinomas (93%). These results indicate that
GATA3 is a very sensitive marker for primary EMPDs in
the genital regions.
GATA3 is a zinc-finger transcription factor involved in
embryogenesis, cell proliferation and differentiation in
multiple human tissues and organs, including breast, geni-
tourinary system, parathyroid, skin, central nervous and
hematopoietic systems [33–36]. In 2007, Higgins et al.
found that GATA3 was a sensitive diagnostic marker for
urothelial carcinoma [37]. Since then, there has been
growing evidence that GATA3 could serve as a relatively
sensitive diagnostic marker for breast carcinomas, para-
thyroid tumors, trophoblastic tumors, mesonephric adeno-
carcinomas, paragangliomas and pheochromocytomas
etc. [28–31, 38–42]. Other tumors with a less frequent
expression of GATA3 include salivary gland tumors,
malignant mesotheliomas, pancreatic adenocarcinomas,
skin squamous cell carcinomas, skin adnexal tumors, renal
oncocytomas, chromophobe renal cell carcinomas, and
yolk sac tumors [28–30]. Morbeck D et al. recently re-
ported positive GATA3 expression in all 11 vulvar primary
Fig. 2 The invasive adenocarcinoma in type Ib disease (primary extramammary Paget disease with invasive adenocarcinoma) (A1: vulva, with
intracytoplasmic mucin; B1: scrotum) showed positive GATA3 staining in all but one cases (A2, B2) (A2 also with intraepithelial disease). Most of
such invasive adenocarcinomas were also positive for GCDFP15 staining (A3, B3). All 3 metastatic adenocarcinomas from vulvar (C1) and 11 of 12
metastatic adenocarcinomas from penoscrotal (D1) extramammary Paget diseases were positive for GATA3 (C2, D2) and most of them were also
positive for GCDFP15 (C3, D3). GATA3 stains more tumor cells than GCDFP15 in some cases (D2, D3)
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EMPDs (4 with invasive carcinoma) [32]. They did not
include any metastatic adenocarcinoma from vulvar Paget
disease. They did not study male genital EMPDs, either.
Our findings and that of Morbeck et al. [32] add primary
genital EMPDs to the list of tumors with high expression
of GATA3. High expression of GATA3 in EMPDs has
some diagnostic implications, both for primary EMPDs
and their metastasis.
Distinguishing primary from secondary EMPDs is clinic-
ally critical given their different treatment and prognosis
[3, 9]. Secondary EMPD in the genital region is usually the
result of intraepithelial spread from a visceral carcinoma,
Fig. 3 Immunohistochemical staining of GATA3 and GCDFP15 in a vulvar primary extra-mammary Paget disease with an underlying apocrine
adenocarcinoma (type Ic disease). The underlying apocrine adenocarcinoma formed a mass in the dermis and subcutaneous tissue but it eroded
the epidermis (a) and grew in a pagetoid pattern within the adjacent epidermis (b, g). The underlying adenocarcinoma showed nests, solid and
glandular growth patterns with some cribriform glands (c, d). Cytoplasmic apical apocrine snouts were apparent (d). Both the underlying invasive
apocrine adenocarcinoma (d) and the overlying intraepithelial Paget disease (g) were positive for GATA3 (e, h) and GCDFP15 (f, i). Similar GATA3
findings were also observed in penoscrotal type Ic diseases
Table 2 Immunohistochemical staining results of GATA3 and GCDFP15 in primary male genital extramammary Paget diseases
Disease Component GATA3 staininga GCDFP15 staininga P value
0 1+ 2+ 3+ 4+ Total 0 1+ 2+ 3+ 4+ Total
Intraepithelial disease
(N = 37)
0 4 (11%) 2 (6%) 2 (6%) 29 (78%) 37 (100%) 19 (51%) 12 (32%) 4 (11%) 0 2 (6%) 18 (49%) < 0.001
Type Ia (N = 21) 1 20 17 4
Type Ib (N = 14) 3 1 2 8 1 7 4 2





2 (13%) 2 (13%) 1 (6%) 10 (63%) 15 (94%) 5 (31%) 6 (38%) 1 (6%) 0 4 (25%) 11 (69%) 0.062
type Ib (N = 14) 1 2 1 1 9 5 5 4





1 (8%) 1 (8%) 1 (8%) 8 (67%) 11 (92%) 2 (17%) 3 (25%) 2 (17%) 1 (8%) 4 (33%) 10 (83%) 0.277
aThe staining is semi-quantitatively scored as follows: 0: < 1% tumor cell staining; 1+: 1–25% tumor cells staining; 2+: 26–50% tumor cells staining; 3+: 51–75%
tumor cells staining; 4+: 76–100% tumor cells staining
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with urogenital tract (urothelial carcinoma, prostate) and
the gastrointestinal tract (distal colon, rectum) being the
most 2 common sources [1–3, 6, 9, 12–16]. In females,
secondary EMPD in vulva caused by urothelial carcinoma
typically involves periurethral vulvar vestibule but it may
extend to the adjacent vulvar skin and it may also become
invasive [1–3, 6, 9, 12–16]. In males, both urothelial car-
cinoma and prostate carcinoma may involve scrotum in
an intraepithelial pagetoid fashion [43–45]. Rarely urothe-
lial carcinoma [43, 46] and prostate adenocarcinoma
[43, 47, 48] may recur in the penis as a secondary
EMPD. Since both primary EMPDs and urothelial
carcinomas are positive for GATA3, GAT3 is not use-
ful in distinguishing primary EMPDs from secondary
EMPD caused by urothelial carcinoma and other
markers should be sought for this purpose. Urothelial
carcinomas are often positive for uroplakin-III, p63
and p40 whereas EMPDs have an opposite immuno-
histochemical profile [49–51]. GCDFP15 is often posi-
tive in primary EMPDs [20–26] but it is only rarely
positive in urothelial carcinoma [43, 52]. Secondary
EMPD caused by prostatic adenocarcinoma can be
distinguished from primary EMPD by p501S (prostein)
and GATA3. Prostatic adenocarcinoma is positive for
p501S but negative for GATA3 whereas EMPD shows an
opposite profile [28–30, 43, 53]. Prostatic adenocarcinoma
can be rarely positive for GCDFP15 and primary EMPDs
can show positive prostate specific antigen (PSA) staining
in as many as 30% cases [43, 53]. Therefore, one cannot
rely on PSA or GCDFP15 to distinguish primary EMPD
from secondary PD caused by prostatic adenocarcinoma.
Secondary EMPDs from anorectal adenocarcinomas typic-
ally extend from perianal skin to the vulva or scrotum
[1–6, 9, 43, 44]. GATA3 is negative in colorectal
adenocarcinoma [28–30] and therefore is useful to
distinguish primary genital EMPD from secondary
EMPD due to colorectal adenocarcinoma. It should
be pointed out that primary EMPDs can be rarely
positive for CDX2 (3%) [43]. GCDFP15 is negative in
colorectal adenocarcinomas [43]. Anorectal adenocar-
cinoma and primary vulvar EMPDs showed overlap-
ping profiles in CK7 and CK20 though CK7 negativity
favors the former and CK20 negativity favors the lat-
ter [43]. In the genital area, rare pagetoid squamous
cell carcinoma in situ can closely mimic intraepithe-
lial EMPD [54, 55] and may be misdiagnosed as such
[54]. Since some squamous cell carcinomas and nor-
mal epidermal cells are positive for GATA3 [28–30],
GATA3 is not useful to distinguish primary EMPD
from pagetoid squamous cell carcinoma in situ. Instead
P63 should be used in this scenario (p63 negative in pri-
mary EMPD but positive in pagetoid squamous cell car-
cinoma in situ) [50, 51]. Lastly, melanoma in situ may
closely mimic primary EMPD and rare pigmented primary
EMPD has been reported [56, 57]. Melanoma in situ was
negative for GATA3 [28–30] but positive for S100,
melan-A and HMB45 whereas EMPD had an opposite
immunoprofile.
Although most primary EMPDs are intraepithelial,
approximately 4% to 20% primary vulvar EMPDs
[1–4, 9, 13, 15, 16] and 26% to 61% primary peno-
scrotal EMPDs were invasive at the time of presentation
[5, 7, 8, 10, 58–61]. Some of these invasive adenocarcin-
omas arise from the intraepithelial EMPD (type Ib primary
EMPDs) whereas others are underlying adenocarcinomas
which showed secondary epidermotropism (type Ic pri-
mary EMPDs) [3, 6, 8, 9, 14–16]. In vulva, it is estimated
that type Ic EMPDs account for at least 10–30% invasive
EMPDs [1–3, 8, 9, 15, 16, 62]. Rare type Ic primary EMPD
in penoscrotum has also been reported [63] and two of
our cases belong to this category. Type Ic EMPDs were re-
ported to be associated with a worse prognosis than type
Ib EMPDs [3, 9] and therefore pathologists should at-
tempt to specify the subtypes of primary invasive EMPDs
(Ib versus Ic). However, it is not always feasible to distin-
guish them. Our findings indicate that type Ib and apo-
crine type Ic diseases cannot be distinguished by their
GATA3 and GCDFP15 immunoprofile given their similar
profile for these two markers. Type Ic EMPDs are pre-
dominantly of apocrine type, but other types of adenocar-
cinomas may also rarely give rise to type Ic EMPDs
including eccrine sweat gland adenocarcinoma [64],
Bartholin gland adenocarcinoma [65], and adenocarcin-
omas of mammary-like glands [66, 67] etc. One of the in-
vasive adenocarcinomas in vulvar type Ic EMPDs in our
study was an eccrine carcinoma. Cutaneous eccrine car-
cinomas were positive for GATA3 in 36% to 68% cases
[68, 69]. The only eccrine carcinoma in our study showed
4+ GATA3 staining (>75% cells). Thus, GATA3 immuno-
staining cannot distinguish type Ib EMPDs from apocrine
and eccrine type Ic primary EMPDs. Their distinction re-
lies on morphology and other markers such as p63 and
GCDFP15. Eccrine carcinomas were often positive p63
(85% to 89%) whereas primary type Ib EMPDs were not
[68, 69]. Eccrine carcinomas were only rarely positive for
GCDFP15 (5%) [69]. Adenocarcinoma of mammary-like
gland in the vulva is rare and its diagnosis requires the
presence of a transition zone between normal mammary-
like glands and adenocarcinoma [66, 67, 70]. Morpho-
logically it is similar to breast carcinoma. Both ductal type
[66] and lobular-like [67] mammary-like carcinomas with
Paget’s disease (type Ic primary EMPD) have been re-
ported. Although there has been no report of GATA3 in
vulvar adenocarcinoma of mammary-like glands, it is con-
ceivable that the vast majority of these tumors will be
positive for GATA3 as in breast carcinoma. As expected,
two thirds of vulvar mammary-like carcinomas were also
positive for GCDFP15 [70]. For these reasons, rare type IC
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primary EMPD due to mammary-like carcinoma cannot
be distinguished from type Ib EMPD or type IC EMPD
due to sweat gland adenocarcinoma by GATA3 and
GCDFP15 immunostaining. Primary type Ic EMPDs
caused by underlying apocrine carcinomas were often
negative for ER and PR. In contrast, vulvar mammary-
like carcinomas were often positive for these two
markers [66, 67, 70–72].
Among patients with invasive EMPDs (type Ib and Ic),
some will develop metastatic disease at the time of presen-
tation or in their subsequent disease courses. In the SEER
data, 17.1% patients with invasive EMPDs have lymph
node metastasis (male 16.0%, female 17.6%) and 2.5% have
distant metastasis (male 3.8%, female 1.9%) at presentation
[4]. In a recent Japanese study of 301 primary invasive
EMPDs (both male and female), 114 (37%) had metastasis
including 20% node metastasis and 17% distant metastasis
(16% with both nodal and distant metastasis) [12]. Lymph
nodes metastasis typically involved inguinofemoral nodes
but pelvic and para-aortic nodes were also involved in
some patients [9–11, 22, 58–62]. Distant metastatic
sites include bone, lung, liver, lung, brain and muscle
[9, 58–62]. Invasive EMPDs were morphologically
similar to other types of tumors especially breast carcin-
oma and urothelial carcinoma, and therefore they may
pose some diagnostic difficulty in metastasis, which can
be further complicated by the fact that patients with pri-
mary EMPDs have an increased risk of developing other
types of secondary primary tumors (overall 5–8% chance).
Breast carcinoma and urothelial carcinoma are among the
most common secondary tumors in these patients, and
they can occur either before or after the diagnosis of pri-
mary EMPDs [6, 9, 12, 14–17, 58–60, 62]. In patients with
both a primary invasive EMPD and another type of tumor
(particularly urothelial and breast carcinoma), the differ-
ential diagnosis for a metastatic tumor with positive
GATA3 staining should also include metastatic primary
EMPDs in the list of differential diagnosis. A panel of im-
munohistochemical markers should be used to facilitate
the correct diagnosis.
GCDFP15 was a useful marker for primary EMPDs
but its sensitivity was 60% to 85% [20–26]. In this study,
we showed that GATA3 is relatively more sensitive than
GCDFP15 for primary EMPDs, especially in male pa-
tients. Our study is the largest series of primary EMPDs
with GCDFP15 staining. It is interesting to note that
GCDFP15 stains a higher percentage of primary EMPDs
in female patients than male patients.
Although GATA3 is a sensitive marker for primary
genital EMPDs, it should be pointed out that it is not
specific for these tumors. As described above and
reviewed elsewhere, several other types of tumors in-
cluding urothelial carcinoma, breast carcinoma, paragan-
gliomas/pheochromocytomas, trophoblastic tumors, and
mesonephric adenocarcinomas are often positive for
GATA3 [28–31, 38–42]. In this sense, GATA3 is less
specific than GCDFP15 for primary genital EMPDs. In
difficult cases particularly in metastasis, both GATA3
and GCDFP15 should be used in conjunction to avoid
misdiagnosis.
Lastly, high expression of GATA3 in primary EMPDs
may also help shed some lights on the histogenesis of
these tumors. Currently there are 3 theories: intraepider-
mal origin of adnexal origin such as apocrine glands,
multipotent stem cells in the epidermis or infundibular
stem cells from hair follicles [1, 2, 20, 73]. Positive stain-
ing for both GATA3 and GCDFP15 in primary EMPDs
probably favors the first theory.
One limitation of our study is that we did not include
genital secondary EMPDs. Secondary EMPDs are rare
and it is difficult to collect a meaningful number of cases
to do a comparison study. The two most common types
of carcinomas that cause secondary EMPDs are urothe-
lial carcinoma and colorectal carcinoma [1–3, 9, 13–17].
As discussed above, GATA3 immunoreactivity was seen
in most urothelial carcinomas but not in colorectal car-
cinomas [28–30, 37].
Conclusions
In summary, we investigated immunohistochemical ex-
pression of GATA3 in a large series of 72 primary
EMPDs in the male and female genital regions. Our
findings show that GATA3 is a very sensitive marker for
genital primary EMPDs and is more sensitive than
GCDFP15. Although GATA3 is highly sensitive for pri-
mary EMPDs, it is not specific for these tumors. GATA3
staining cannot distinguish intraepithelial PD from page-
toid squamous cell carcinoma in situ or primary EMPD
from secondary EMPD caused by urothelial carcinoma.
GATA3 staining can be used to distinguish primary
EMPD from pagetoid melanoma in situ and secondary
EMPD caused by colorectal carcinoma. In the metastatic
setting, GATA3-positive tumors should include meta-
static adenocarcinoma originated from PD.
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